TY - JOUR
T1 - Emerging therapy for the treatment of acute lymphoblastic leukemia
AU - Fullmer, Amber
AU - O'Brien, Susan
AU - Kantarjian, Hagop
AU - Jabbour, Elias
PY - 2010/3
Y1 - 2010/3
N2 - Importance of the field: Over the last few decades, advances in acute lymphoblastic leukemia (ALL) therapy have led to long-term survival rates of >80% in children; however, comparable rates have yet to be achieved in adults, and a large majority of patients relapse from their disease. Areas covered in this review: The review describes historical therapy and advancements in ALL treatment over the past few decades, while providing a concise review of the future direction of ALL therapy. Literature was collected through peer reviewed journals and the Pharmaprojects drug profile for ALL. What the reader will gain: Current information regarding prognostic factors for relapse, salvage therapy options and emerging drugs are provided in the review. Take home message: Development of new drugs with novel mechanisms, unique formulations of existing medications, as well as manipulation of current combinations of drugs remain vital to the success in adult ALL.
AB - Importance of the field: Over the last few decades, advances in acute lymphoblastic leukemia (ALL) therapy have led to long-term survival rates of >80% in children; however, comparable rates have yet to be achieved in adults, and a large majority of patients relapse from their disease. Areas covered in this review: The review describes historical therapy and advancements in ALL treatment over the past few decades, while providing a concise review of the future direction of ALL therapy. Literature was collected through peer reviewed journals and the Pharmaprojects drug profile for ALL. What the reader will gain: Current information regarding prognostic factors for relapse, salvage therapy options and emerging drugs are provided in the review. Take home message: Development of new drugs with novel mechanisms, unique formulations of existing medications, as well as manipulation of current combinations of drugs remain vital to the success in adult ALL.
KW - Acute lymphoblastic leukemia
KW - Emerging treatment
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=77749261179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77749261179&partnerID=8YFLogxK
U2 - 10.1517/14728210903456026
DO - 10.1517/14728210903456026
M3 - Review article
C2 - 20055690
AN - SCOPUS:77749261179
SN - 1472-8214
VL - 15
SP - 1
EP - 11
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
IS - 1
ER -